|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
|
US6991790B1
(en)
*
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
|
US6171586B1
(en)
*
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
AU4685900A
(en)
|
1999-04-30 |
2000-11-17 |
La Jolla Institute For Allergy And Immunology |
Methods for preventing reactivation of latent virus and controlling virus replication
|
|
US7112576B1
(en)
|
1999-12-10 |
2006-09-26 |
Regents Of The University Of Minnesota |
Compositions and methods for cryopreservation of peripheral blood lymphocytes
|
|
ATE442862T2
(de)
|
2000-10-12 |
2009-10-15 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US7083787B2
(en)
*
|
2000-11-15 |
2006-08-01 |
Globeimmune, Inc. |
Yeast-dendritic cell vaccines and uses thereof
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20020141970A1
(en)
*
|
2001-03-05 |
2002-10-03 |
Pettit Dean K. |
Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
CA2470511C
(en)
|
2001-12-21 |
2014-05-27 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
|
BR0215218A
(pt)
*
|
2001-12-21 |
2004-11-16 |
Novo Nordisk As |
Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
|
|
DE10204792A1
(de)
*
|
2002-02-06 |
2003-08-14 |
Merck Patent Gmbh |
Lyophilisierte Zubereitung enthaltend Immuncytokine
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
CN1671410B
(zh)
|
2002-06-21 |
2010-05-12 |
诺和诺德医疗保健公司 |
因子ⅶ多肽的稳定化固体组合物
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
JP2006516639A
(ja)
*
|
2003-02-01 |
2006-07-06 |
ニユーララブ・リミテツド |
可溶性Ａ−βに対する抗体を生成させるための能動免疫
|
|
JP2006524195A
(ja)
*
|
2003-03-18 |
2006-10-26 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
BRPI0403964B8
(pt)
*
|
2003-04-04 |
2021-05-25 |
Genentech Inc |
formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
|
|
BRPI0409936A
(pt)
|
2003-05-23 |
2006-04-25 |
Novo Nordisk Healthcare Ag |
uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
|
|
TWI306458B
(en)
*
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
JP4658041B2
(ja)
*
|
2003-06-25 |
2011-03-23 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Ｖｉｉ因子ポリペプチドの液体組成物
|
|
EP1644030B1
(en)
*
|
2003-07-01 |
2009-10-28 |
Novo Nordisk Health Care AG |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
|
MXPA06001698A
(es)
|
2003-08-14 |
2006-05-19 |
Novo Nordisk Healthcare Ag |
Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
|
|
WO2005058283A2
(en)
|
2003-12-19 |
2005-06-30 |
Novo Nordisk Health Care Ag |
Stabilised compositions of factor vii polypeptides
|
|
AU2005228945B2
(en)
|
2004-03-19 |
2010-09-30 |
Baxter Healthcare S.A. |
Factor IXa for the treatment of bleeding disorders
|
|
WO2006005058A2
(en)
*
|
2004-06-30 |
2006-01-12 |
Nektar Therapeutics Al, Corporation |
Polymer-factor ix moiety conjugates
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
ES2396555T3
(es)
*
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
|
PE20061401A1
(es)
*
|
2004-12-15 |
2006-12-23 |
Neuralab Ltd |
ANTICUERPOS Aß PARA MEJORAR LA COGNICION
|
|
EP1838348B1
(en)
|
2004-12-15 |
2013-06-26 |
Janssen Alzheimer Immunotherapy |
Humanized amyloid beta antibodies for use in improving cognition
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
PA8661401A1
(es)
*
|
2005-01-28 |
2006-09-08 |
Wyeth Corp |
Formulaciones del liquido polipeptido estabilizado
|
|
EP1913159B1
(en)
*
|
2005-06-30 |
2010-12-01 |
GE Healthcare Bio-Sciences Corp. |
Detection method for gene expression
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
RU2432155C3
(ru)
|
2006-06-16 |
2017-11-17 |
Ридженерон Фармасьютикалз, Инк. |
Составы антагониста vegf, подходящие для интравитреального введения
|
|
AU2007234612B2
(en)
*
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
US8449520B2
(en)
*
|
2007-03-19 |
2013-05-28 |
HemCon Medical Technologies Inc. |
Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
CN103990116A
(zh)
|
2007-04-26 |
2014-08-20 |
拜尔健康护理有限责任公司 |
稳定用于冷冻储藏的重组蛋白液体溶液的方法
|
|
US7879805B2
(en)
*
|
2007-06-01 |
2011-02-01 |
Acologix, Inc. |
High temperature stable peptide formulation
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
DK2182983T3
(da)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
|
|
CA2695697A1
(en)
|
2007-08-07 |
2009-02-12 |
Advanced Technologies And Regenerative Medicine, Llc |
Protein formulations comprising gdf-5 in aqueous acidic solution
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
BRPI0911048A2
(pt)
*
|
2008-04-14 |
2015-12-29 |
Atrm Llc |
formulações líquidas tamponadas de gdf-5
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
EP2538967A1
(en)
*
|
2010-02-24 |
2013-01-02 |
Arecor Limited |
Stable compositions of factor ix
|
|
HUE047173T2
(hu)
|
2010-03-01 |
2020-04-28 |
Bayer Healthcare Llc |
Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
SG10201707600XA
(en)
*
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
EP3933384A1
(en)
*
|
2013-03-15 |
2022-01-05 |
Hycor Biomedical, LLC |
Device and associated method for performing luminescence and fluorescence measurements of a sample
|
|
US10772942B2
(en)
*
|
2014-03-24 |
2020-09-15 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
|
DK3384049T3
(da)
|
2015-12-03 |
2023-10-02 |
Regeneron Pharma |
Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
|
|
CN111295094A
(zh)
|
2017-10-09 |
2020-06-16 |
泰尔茂比司特生物技术有限公司 |
冻干容器及使用冻干容器的方法
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
WO2020242552A1
(en)
|
2019-03-14 |
2020-12-03 |
Terumo Bct Biotechnologies, Llc |
Multi-part lyophilization container and method of use
|